Clinical Analysis of Bacterial Infection Characteristics in Lymphoma Patients with High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation-A Single-Centered Retrospective Study


Цитировать

Полный текст

Аннотация

Background:High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/AHSCT) is used to treat lymphoma. Although AHSCT has made considerable strides and become safer, HDT-AHSCT infection continues to be a leading cause of morbidity and mortality associated with transplantation.

Objective:To characterise pathogenic bacterial infections in HDT/AHSCT-treated lymphoma patients. The prevalence of pathogenic microorganisms and the timing of foci after transplantation, along with bloodstream infection (BSI) risk factors, can help determine the need for empirical antibiotics after AHSCT.

Methods:We retrospectively analyzed 133 lymphoma patients treated by HDT/AHSCT from April 2017 to October 2021 at Peking University International Hospital, Beijing, China. We analyzed their clinical characteristics, microbiological distribution characteristics, and BSI risk factors in detail.

Results:In order, intestinal infection (56 cases), BSI (17 cases), pulmonary (12 cases), upper respiratory tract (5 cases), and perianal (4 cases) were the most common locations of infection after HDT/AHSCT. The infection sites yielded 92 putative pathogenic pathogens, with bacteria predominating (61.96%), fungi (28.26%), viruses (5.43%), and mycoplasma (4.35%). Gram-negative bacteria (GNB) strains outnumbered gram-positive bacteria (GPB) strains (73.68%). Two strains of Escherichia coli produced extended-spectrum β-lactamase (ESBL) and one strain of carbapenem-resistant enterobacteriaceae (CRE). Methicillin-resistant Staphylococcus epidermidis (MRSE) had one strain. BSI was caused by Escherichia coli (82.35%), Intestinal mucositis (23.52%), and catheter-associated infections (11.76%). Age, CD34, pretreatment regimen, antibiotic regimen, and past chemotherapeutic agent lung damage were BSI risk variables in univariate analysis. CD34 and past chemotherapeutic drug lung damage were the primary causes of BSI after HDT/AHSCT for lymphoma.

Conclusion:High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/AHSCT) is used to treat lymphoma. Although AHSCT has made considerable strides and become safer, HDT-AHSCT infection continues to be a leading cause of morbidity and mortality associated with transplantation.

Об авторах

Dan-Hui Sun

Department of Infectious Diseases, Peking University International Hospital

Email: info@benthamscience.net

Di Mei

Department of Lymphoma, Peking University International Hospital

Email: info@benthamscience.net

Xiao-Qin Yao

Department of Traditional Chinese Medicine, Peking University International Hospital

Email: info@benthamscience.net

Yi-Hui Rong

Department of Infectious Diseases, Peking University International Hospital

Email: info@benthamscience.net

Gui-Qiang Wang

Department of Infectious Diseases, Peking University International Hospital

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Kanate, A.S.; Kumar, A.; Dreger, P.; Dreyling, M.; Le Gouill, S.; Corradini, P.; Bredeson, C.; Fenske, T.S.; Smith, S.M.; Sureda, A.; Moskowitz, A.; Friedberg, J.W.; Inwards, D.J.; Herrera, A.F.; Kharfan-Dabaja, M.A.; Reddy, N.; Montoto, S.; Robinson, S.P.; Abutalib, S.A.; Gisselbrecht, C.; Vose, J.; Gopal, A.; Shadman, M.; Perales, M.A.; Carpenter, P.; Savani, B.N.; Hamadani, M. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol., 2019, 5(5), 715-722. doi: 10.1001/jamaoncol.2018.6278 PMID: 30816957
  2. Wisplinghoff, H.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis., 2003, 36(9), 1103-1110. doi: 10.1086/374339 PMID: 12715303
  3. Klastersky, J.; Ameye, L.; Maertens, J.; Georgala, A.; Muanza, F.; Aoun, M.; Ferrant, A.; Rapoport, B.; Rolston, K.; Paesmans, M. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents, 2007, 30(S1), 51-59. doi: 10.1016/j.ijantimicag.2007.06.012 PMID: 17689933
  4. Gudiol, C.; Bodro, M.; Simonetti, A.; Tubau, F.; González-Barca, E.; Cisnal, M.; Domingo-Domenech, E.; Jiménez, L.; Carratalà, J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin. Microbiol. Infect., 2013, 19(5), 474-479. doi: 10.1111/j.1469-0691.2012.03879.x PMID: 22524597
  5. Garcia Borrega, J.; Böll, B.; Kochanek, M.; Naendrup, J.H.; Simon, F.; Sieg, N.; Hallek, M.; Borchmann, P.; Holtick, U.; Shimabukuro-Vornhagen, A.; Eichenauer, D.A.; Heger, J.M. Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: A single-center retrospective analysis. Ann. Hematol., 2023, 102(1), 191-197. doi: 10.1007/s00277-022-05028-x PMID: 36394583
  6. Ferreri, A.J.M.; Cwynarski, K.; Pulczynski, E.; Fox, C.P.; Schorb, E.; Celico, C.; Falautano, M.; Nonis, A.; La Rosée, P.; Binder, M.; Fabbri, A.; Ilariucci, F.; Krampera, M.; Roth, A.; Hemmaway, C.; Johnson, P.W.; Linton, K.M.; Pukrop, T.; Gørløv, J.S.; Balzarotti, M.; Hess, G.; Keller, U.; Stilgenbauer, S.; Panse, J.; Tucci, A.; Orsucci, L.; Pisani, F.; Zanni, M.; Krause, S.W.; Schmoll, H.J.; Hertenstein, B.; Rummel, M.; Smith, J.; Thurner, L.; Cabras, G.; Pennese, E.; Ponzoni, M.; Deckert, M.; Politi, L.S.; Finke, J.; Ferranti, A.; Cozens, K.; Burger, E.; Ielmini, N.; Cavalli, F.; Zucca, E.; Illerhaus, G. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36(7), 1870-1878. doi: 10.1038/s41375-022-01582-5 PMID: 35562406
  7. Dhakal, B.; Szabo, A.; Chhabra, S.; Hamadani, M.; D’Souza, A.; Usmani, S.Z.; Sieracki, R.; Gyawali, B.; Jackson, J.L.; Asimakopoulos, F.; Hari, P.N. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction. JAMA Oncol., 2018, 4(3), 343-350. doi: 10.1001/jamaoncol.2017.4600 PMID: 29302684
  8. Karagiannis, P.; Sänger, L.; Alsdorf, W.; Weisel, K.; Fiedler, W.; Kluge, S.; Wichmann, D.; Bokemeyer, C.; Fuhrmann, V. Intensive care outcomes of patients after high dose chemotherapy and subsequent autologous stem cell transplantation: A retrospective, single centre analysis. Cancers., 2020, 12(6), 1678. doi: 10.3390/cancers12061678 PMID: 32599837
  9. Nassar, A.P., Jr; Archanjo, L.V.F.; Ranzani, O.T.; Zampieri, F.G.; Salluh, J.I.F.; Cavalcanti, G.F.R.; Moreira, C.E.N.; Viana, W.N.; Costa, R.; Melo, U.O.; Roderjan, C.N.; Correa, T.D.; de Almeida, S.L.S.; Azevedo, L.C.P.; Maia, M.O.; Cravo, V.S.; Bozza, F.A.; Caruso, P.; Soares, M. Characteristics and outcomes of autologous hematopoietic stem cell transplant recipients admitted to intensive care units: A multicenter study. J. Crit. Care, 2022, 71, 154077. doi: 10.1016/j.jcrc.2022.154077 PMID: 35636348
  10. Michel, C.S.; Teschner, D.; Schmidtmann, I.; Theobald, M.; Hauptrock, B.; Wagner-Drouet, E.M.; Radsak, M.P. Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. Sci. Rep., 2019, 9(1), 19911. doi: 10.1038/s41598-019-56322-0 PMID: 31882648
  11. Eyre, T.A.; Barrington, S.F.; Okosun, J. Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant. Haematologica, 2022, 108(3), 785-796. doi: 10.3324/haematol.2021.280287 PMID: 35586966
  12. Wingard, J.R.; Hsu, J.; Hiemenz, J.W. Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology. Hematol. Oncol. Clin. North Am., 2011, 25(1), 101-116. doi: 10.1016/j.hoc.2010.11.008 PMID: 21236393
  13. Dropulic, L.K.; Lederman, H.M. Overview of infections in the immunocompromised host. Microbiol. Spectr., 2016, 4(4), 1-15.
  14. Maschmeyer, G.; Haas, A. The epidemiology and treatment of infections in cancer patients. Int. J. Antimicrob. Agents, 2008, 31(3), 193-197. doi: 10.1016/j.ijantimicag.2007.06.014 PMID: 17703922
  15. Safdar, A.; Armstrong, D. Infectious morbidity in critically ill patients with cancer. Crit. Care Clin., 2001, 17(3), 531-570, vii-viii. doi: 10.1016/S0749-0704(05)70198-6 PMID: 11525048
  16. Robak, T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther., 2008, 8(7), 1033-1051. doi: 10.1586/14737140.8.7.1033 PMID: 18588450
  17. Elter, T.; Vehreschild, J.J.; Gribben, J.; Cornely, O.A.; Engert, A.; Hallek, M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann. Hematol., 2009, 88(2), 121-132. doi: 10.1007/s00277-008-0566-9 PMID: 18682948
  18. Zambelli, A.; Montagna, D.; Da Prada, G.A.; Maccario, R.; Zibera, C.; Moretta, A.; Ponchio, L.; Lozza, L.; Baiardi, P.; Maserati, R.; Marone, P.; Della Cuna, G.R. Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res., 2002, 22(6B), 3701-3708. PMID: 12552979
  19. McCann, S.; Schwenkglenks, M.; Bacon, P.; Einsele, H.; D’Addio, A.; Maertens, J.; Niederwieser, D.; Rabitsch, W.; Roosaar, A.; Ruutu, T.; Schouten, H.; Stone, R.; Vorkurka, S.; Quinn, B.; Blijlevens, N. The prospective oral mucositis audit: Relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant., 2009, 43(2), 141-147. doi: 10.1038/bmt.2008.299 PMID: 18776926
  20. Carbone, P.P.; Kaplan, H.S.; Musshoff, K.; Smithers, D.W.; Tubiana, M. Report of the committee on hodgkin’s disease staging classification. Cancer Res., 1971, 31(11), 1860-1861. PMID: 5121694
  21. Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 1982, 5(6), 649-656. doi: 10.1097/00000421-198212000-00014 PMID: 7165009
  22. Freifeld, A.G.; Bow, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.H.; Wingard, J.R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis., 2011, 52(4), e56-e93. doi: 10.1093/cid/cir073 PMID: 21258094
  23. Hughes, W.T.; Armstrong, D.; Bodey, G.P.; Bow, E.J.; Brown, A.E.; Calandra, T.; Feld, R.; Pizzo, P.A.; Rolston, K.V.I.; Shenep, J.L.; Young, L.S. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis., 2002, 34(6), 730-751. doi: 10.1086/339215 PMID: 11850858
  24. Chinese Medical Association, Haematology Branch, Chinese Physicians Association, Haematologist Branch. Clinical application guidelines for antimicrobial drugs in patients with neutrophil deficiency with fever in China (2020 edition). Zhonghua Xue Ye Xue Za Zhi, 2020, 41(12), 969-978. PMID: 33445842
  25. Collin, B.A.; Leather, H.L.; Wingard, J.R.; Ramphal, R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin. Infect. Dis., 2001, 33(7), 947-953. doi: 10.1086/322604 PMID: 11528564
  26. Ogonek, J.; Kralj Juric, M.; Ghimire, S.; Varanasi, P.R.; Holler, E.; Greinix, H.; Weissinger, E. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front. Immunol., 2016, 7, 507. doi: 10.3389/fimmu.2016.00507 PMID: 27909435
  27. Marchesi, F.; Pimpinelli, F.; Di Domenico, E.; Renzi, D.; Gallo, M.; Regazzo, G.; Rizzo, M.; Gumenyuk, S.; Toma, L.; Marino, M.; Cordone, I.; Cantonetti, M.; Liberati, A.; Montanaro, M.; Ceribelli, A.; Prignano, G.; Palombi, F.; Romano, A.; Papa, E.; Pisani, F.; Spadea, A.; Arcese, W.; Ensoli, F.; Mengarelli, A. Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: Opportunistic partnership or cause-effect relationship? Int. J. Mol. Sci., 2019, 20(6), 1373. doi: 10.3390/ijms20061373 PMID: 30893777
  28. Kontoyiannis, D.P.; Marr, K.A.; Park, B.J.; Alexander, B.D.; Anaissie, E.J.; Walsh, T.J.; Ito, J.; Andes, D.R.; Baddley, J.W.; Brown, J.M.; Brumble, L.M.; Freifeld, A.G.; Hadley, S.; Herwaldt, L.A.; Kauffman, C.A.; Knapp, K.; Lyon, G.M.; Morrison, V.A.; Papanicolaou, G.; Patterson, T.F.; Perl, T.M.; Schuster, M.G.; Walker, R.; Wannemuehler, K.A.; Wingard, J.R.; Chiller, T.M.; Pappas, P.G. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin. Infect. Dis., 2010, 50(8), 1091-1100. doi: 10.1086/651263 PMID: 20218877
  29. Sharrack, B.; Saccardi, R.; Alexander, T.; Badoglio, M.; Burman, J.; Farge, D.; Greco, R.; Jessop, H.; Kazmi, M.; Kirgizov, K.; Labopin, M.; Mancardi, G.; Martin, R.; Moore, J.; Muraro, P.A.; Rovira, M.; Sormani, M.P.; Snowden, J.A. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant., 2020, 55(2), 283-306. doi: 10.1038/s41409-019-0684-0 PMID: 31558790
  30. Kato, H.; Yamamoto, K.; Matsuo, K.; Oki, Y.; Taji, H.; Kuwatsuka, Y.; Seto, M.; Kagami, Y.; Morishima, Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: Association with an incremental risk of infectious events. Ann. Oncol., 2010, 21(8), 1699-1705. doi: 10.1093/annonc/mdq008 PMID: 20172906
  31. Arango, J.I.; Restrepo, A.; Schneider, D.L.; Callander, N.S.; Ochoa-Bayona, J.L.; Restrepo, M.I.; Bradshaw, P.; Patterson, J.; Freytes, C.O. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant., 2006, 37(5), 517-521. doi: 10.1038/sj.bmt.1705269 PMID: 16435018
  32. Teira, P.; Battiwalla, M.; Ramanathan, M.; Barrett, A.J.; Ahn, K.W.; Chen, M.; Green, J.S.; Saad, A.; Antin, J.H.; Savani, B.N.; Lazarus, H.M.; Seftel, M.; Saber, W.; Marks, D.; Aljurf, M.; Norkin, M.; Wingard, J.R.; Lindemans, C.A.; Boeckh, M.; Riches, M.L.; Auletta, J.J. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127(20), 2427-2438. doi: 10.1182/blood-2015-11-679639 PMID: 26884374
  33. Lark, R.L.; McNeil, S.A.; VanderHyde, K.; Noorani, Z.; Uberti, J.; Chenoweth, C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin. Infect. Dis., 2001, 33(3), 338-343. doi: 10.1086/322595 PMID: 11438899
  34. Ruescher, T.J.; Sodeifi, A.; Scrivani, S.J.; Kaban, L.B.; Sonis, S.T. The impact of mucositis on? -hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer, 1998, 82(11), 2275-2281. doi: 10.1002/(SICI)1097-0142(19980601)82:113.0.CO;2-Q PMID: 9610710
  35. Bochud, P.Y.; Eggiman, P.; Calandra, T.; Van Melle, G.; Saghafi, L.; Francioli, P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin. Infect. Dis., 1994, 18(1), 25-31. doi: 10.1093/clinids/18.1.25 PMID: 8054434
  36. Labarca, J.A.; Leber, A.L.; Kern, V.L.; Territo, M.C.; Brankovic, L.E.; Bruckner, D.A.; Pegues, D.A. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: Role of severe neutropenia and mucositis. Clin. Infect. Dis., 2000, 30(1), 195-197. doi: 10.1086/313591 PMID: 10619754
  37. Vollaard, E.J.; Clasener, H.A. Colonization resistance. Antimicrob. Agents Chemother., 1994, 38(3), 409-414. doi: 10.1128/AAC.38.3.409 PMID: 8203832
  38. Endt, K.; Stecher, B.; Chaffron, S.; Slack, E.; Tchitchek, N.; Benecke, A.; Van Maele, L.; Sirard, J.C.; Mueller, A.J.; Heikenwalder, M.; Macpherson, A.J.; Strugnell, R.; von Mering, C.; Hardt, W.D. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog., 2010, 6(9), e1001097. doi: 10.1371/journal.ppat.1001097 PMID: 20844578
  39. Van der Waaij, D.; Berghuis-de, V.J.M.; Lekkerkerk-van der Wees, J.E.C. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J. Hyg., 1971, 69(3), 405-411. doi: 10.1017/S0022172400021653 PMID: 4999450
  40. Hu, F.P.; Zhu, D.M.; Wang, F. CHINET 2013 surveillance of bacterial resistance in China. Chin. J. Infect. Chemother., 2014, 14, 369-378.
  41. Heinz, W.J.; Buchheidt, D.; Christopeit, M.; von Lilienfeld-Toal, M.; Cornely, O.A.; Einsele, H.; Karthaus, M.; Link, H.; Mahlberg, R.; Neumann, S.; Ostermann, H.; Penack, O.; Ruhnke, M.; Sandherr, M.; Schiel, X.; Vehreschild, J.J.; Weissinger, F.; Maschmeyer, G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann. Hematol., 2017, 96(11), 1775-1792. doi: 10.1007/s00277-017-3098-3 PMID: 28856437
  42. Kwon, J.C.; Kim, S.H.; Choi, J.K.; Cho, S.Y.; Park, Y.J.; Park, S.H.; Choi, S.M.; Lee, D.G.; Choi, J.H.; Yoo, J.H. Epidemiology and clinical features of bloodstream infections in hematology wards: One year experience at the catholic blood and marrow transplantation center. Infect. Chemother., 2013, 45(1), 51-61. doi: 10.3947/ic.2013.45.1.51 PMID: 24265950
  43. Wang, F.; Zhu, D.M.; Hu, F.P. 2012 CHINET surveillance of bacterial resistance in China. Chin J Infect Chemother, 2013, 13, 321-330.
  44. Katsios, C.M.; Burry, L.; Nelson, S.; Jivraj, T.; Lapinsky, S.E.; Wax, R.S.; Christian, M.; Mehta, S.; Bell, C.M.; Morris, A.M. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit. Care, 2012, 16(6), R216. doi: 10.1186/cc11854 PMID: 23127353
  45. Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002, 34(7), 909-917. doi: 10.1086/339202 PMID: 11880955
  46. Marr, K.A.; Carter, R.A.; Boeckh, M.; Martin, P.; Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood, 2002, 100(13), 4358-4366. doi: 10.1182/blood-2002-05-1496 PMID: 12393425
  47. Veeraputhiran, M.; Jain, T.; Deol, A.; Ayash, L.; Kim, S.; Dyson, G.; Bhutani, D.; Lum, L.G.; Ratanatharathorn, V.; Uberti, J.P.; Abidi, M.H. BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin. Lymphoma Myeloma Leuk., 2015, 15(9), 531-535. doi: 10.1016/j.clml.2015.05.008 PMID: 26166312
  48. Yoon, D.H.; Sohn, B.S.; Jang, G.; Kim, E.K.; Kang, B.W.; Kim, C.; Kim, J.E.; Kim, S.; Lee, D.H.; Lee, J.S.; Park, S.J.; Park, C.J.; Huh, J.; Suh, C. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion, 2009, 49(9), 1890-1900. doi: 10.1111/j.1537-2995.2009.02202.x PMID: 19453991
  49. Mikulska, M.; Del Bono, V.; Bruzzi, P.; Raiola, A.M.; Gualandi, F.; Van Lint, M.T.; Bacigalupo, A.; Viscoli, C. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection, 2012, 40(3), 271-278. doi: 10.1007/s15010-011-0229-y PMID: 22187340
  50. Scott, B.L.; Park, J.Y.; Deeg, H.J.; Marr, K.A.; Boeckh, M.; Chauncey, T.R.; Appelbaum, F.R.; Storb, R.; Storer, B.E. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol. Blood Marrow Transplant., 2008, 14(7), 799-806. doi: 10.1016/j.bbmt.2008.04.011 PMID: 18541200
  51. Singh, R.K.; Kumar, S.; Prasad, D.N.; Bhardwaj, T.R. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. Eur. J. Med. Chem., 2018, 151, 401-433. doi: 10.1016/j.ejmech.2018.04.001 PMID: 29649739
  52. Reece, D.E.; Nevill, T.J.; Sayegh, A.; Spinelli, J.J.; Brockington, D.A.; Barnett, M.J.; Klingemann, H-G.; Connors, J.M.; Nantel, S.H.; Shepherd, J.D.; Sutherland, H.J.; Voss, N.J.S.; Fairey, R.N.; O’Reilly, S.E.; Phillips, G.L. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant., 1999, 23(11), 1131-1138. doi: 10.1038/sj.bmt.1701790 PMID: 10382952
  53. Benekli, M.; Smiley, S.L.; Younis, T.; Czuczman, M.S.; Hernandez-Ilizaliturri, F.; Bambach, B.; Battiwalla, M.; Padmanabhan, S.; McCarthy, P.L., Jr; Hahn, T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant., 2008, 41(7), 613-619. doi: 10.1038/sj.bmt.1705951 PMID: 18071290

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024